ABIVAX has appointed Didier Blondel as Chief Financial Officer, effective January 2nd, 2017.
Didier Blondel
Blondel has worked for past 20 years for Sanofi. Since 2012 he was Chief Financial Officer at Sanofi Pasteur MSD, a Lyon-based joint-venture between Sanofi and Merck, and European leader in human vaccines.
Alain Chevallier, currently CFO of ABIVAX, will transition to new professional opportunities at Truffle Capital, the majority shareholder of ABIVAX. Chevallier will continue as a Senior Advisor at ABIVAX.